41 completed, 5 withdrawn, 4 terminated, 4 unknown. 17 Phase 1, 14 Phase 3, 10 Phase 4, 7 Phase 2, 5 Not applicable.
Follow Dexlansoprazole: new trials by email Literature Review of Dexlansoprazole trials Research Report on Dexlansoprazole
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1 Dexlansoprazole Delayed-Release Capsules for Acid-Related Disorders in Infants Aged 1 to 11 Months Dexlansoprazole - Pediatric Gastroesophageal Reflux Disease | Phase 1 | Withdrawn | Takeda | 2025-06-15 | 2020-04-15 | |
| Therapeutic Effect of Vonoprazan Versus Dexlansoprazole in Treatment of Gastroesophageal Reflux Disease Dexlansoprazole 60 mg, Vonoprazan 20 mg bid - Vonoprazan, Proton Pump Inhibitor | Phase 4 | Completed | Ayman Magd Eldin Mohammad Sadek | 136 | 2024-10-01 | 2025-02-27 |
| A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old Dexlansoprazole - Erosive Esophagitis | Phase 2 | Terminated | Takeda | 24 | 2023-05-23 | 2026-05-06 |
| A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old Dexlansoprazole - Gastroesophageal Reflux Disease (GERD) | Phase 2 | Completed | Takeda | 71 | 2023-02-20 | 2026-07-29 |
| Bioequivalence Study of DelanzoᵀᴹDR 60mg (Dexlansoprazole) Capsule With Dexilant® 60mg (Dexlansoprazole) Capsule in Healthy Pakistani Subjects. Dexlansoprazole - Healthy, Bioequivalence Study | Phase 1 | Completed | University of Karachi | 60 | 2021-09-18 | 2023-11-29 |
| Effect of H2 Receptor Antagonist and Proton Pump Inhibitor on the Positivity Rates and Clinical Outcomes of COVID-19 No intervention (Retrospective Cohort Observational) - COVID-19 | Completed | Seoul National University Hospital | 400000 | 2021-05-01 | 2024-11-29 | |
| A Study to Compare the Bioavailability (BA) of Dexlansoprazole Delayed-release Capsules 30 mg dexlansoprazole capsules manufactured at TOB, 30 mg dexlansoprazole capsules manufactured at TPC, 60 mg dexlansoprazole capsules manufactured at TOB - Healthy Volunteers | Phase 1 | Completed | Takeda | 122 | 2019-01-10 | 2020-03-19 |
| Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors levothyroxine sodium capsule, Proton pump inhibitor (PPI), Levothyroxine Sodium (LT4) Tablets - Hypothyroidism;Postablative | Phase 4 | Completed | IBSA Institut Biochimique SA | 66 | 2018-07-30 | 2022-04-05 |
| A Study to Evaluate the Pharmacokinetics of Dexlansoprazole 30 Milligram (mg) and 60 mg Delayed-release Capsules in Healthy Chinese Participants Dexlansoprazole - Healthy Volunteers | Phase 1 | Completed | Takeda | 40 | 2017-11-22 | 2019-05-10 |
| Comparison of the Efficiency of Two Different PPI Formula in Atypical GERD dexilansoprazole (Dexilant 60 mg), lansoprazole (Takepron OD 30 mg) - Compare the Response Rate of Atypical GERD After PPI Therapy | Not applicable | Unknown | Taipei Veterans General Hospital, Taiwan | 120 | 2017-08-01 | 2018-02-01 |
| Effectiveness of Physiologic Testing in PPI Non-Responders dexlansoprazole - Gastro Esophageal Reflux | Early Phase 1 | Completed | Northwestern University | 240 | 2017-07-01 | 2023-01-12 |
| A Clinical Trial to Evaluate the Safety and Tolerability of Dexlansoprazole Injection in Healthy Chinese Adults（Part 2） Dexlansoprazole Injection, Lansoprazole Injection - Effect of Drugs, Safety Issues | Phase 1 | Unknown | First Affiliated Hospital of Zhejiang University | 70 | 2017-05-05 | 2017-04-19 |
| Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants 30 mg dexlansoprazole capsules manufactured at TOB, 30 mg dexlansoprazole capsules manufactured at TPC, 60 mg dexlansoprazole capsules manufactured at TOB - Healthy Volunteers | Phase 1 | Completed | Takeda | 116 | 2017-04-25 | 2019-06-14 |
| An Open-Label Trial of Dexlansoprazole 60mg for the Relief of Heartburn During the Fasting Month of Ramadan Dexlansoprazole 60 MG - GERD, Proton Pump Inhibitor | Phase 4 | Completed | American University of Beirut Medical Center | 33 | 2017-02-27 | 2017-09-15 |
| Once Daily Dose Dexlansoprazole Quadruple Therapy for Helicobacter Pylori Dexlansoprazole 60 mg once daily - H Pylori Eradication | Phase 4 | Completed | Ramathibodi Hospital | 180 | 2017-01-01 | 2018-04-03 |
| A Clinical Trial to Evaluate the Safety and Tolerability of Dexlansoprazole Injection in Healthy Chinese Adults (Part 1) dexlansoprazole injection, placebo - Safety Issues | Phase 1 | Completed | First Affiliated Hospital of Zhejiang University | 28 | 2017-01-01 | 2017-03-16 |
| Efficacy and Safety of Dexlansoprazole on Heartburn Relief in Chinese Patients Dexlansoprazole, Placebo - Heartburn, Gastroesophageal Reflux Disease | Phase 3 | Completed | Takeda | 217 | 2016-12-27 | 2019-07-05 |
| Efficacy and Safety of Dexlansoprazole in Healing and Maintaining Healing of Erosive Esophagitis Dexlansoprazole, Lansoprazole, Placebo - Erosive Esophagitis | Phase 3 | Terminated | Takeda | 37 | 2016-12-21 | 2019-02-22 |
| Treatment Effect Between Dexlansoprazole and Double-dose Lansoprazole in Obesity Patients With Reflux Esophagitis Dexlansoprazole, Lansoprazole - Gastroesophageal Reflux Disease | Phase 4 | Unknown | National Cheng-Kung University Hospital | 200 | 2015-10-01 | 2016-05-03 |
| Pharmacodynamic Properties of CJ-12420 on Evening Dosing Dexlansoprazole 60 MG, CJ-12420 50mg, CJ-12420 100mg - Healthy | Phase 1 | Completed | HK inno.N Corporation | 24 | 2015-05-13 | 2017-02-06 |
Showing 20 of 54. Sign in to see all of them.
Gastroesophageal Reflux (26) · Heartburn (9) · Esophagitis, Peptic (6) · Laryngopharyngeal Reflux (4) · Barrett Esophagus (2) · Deglutition Disorders (2) · Eosinophilic Esophagitis (2) · COVID-19 (1) · Chest Pain (1) · Cough (1) · Gastritis, Atrophic (1) · Globus Sensation (1) · Head and Neck Neoplasms (1) · Helicobacter Infections (1) · Inflammation (1)
Takeda (29) · First Affiliated Hospital of Zhejiang University (2) · Mayo Clinic (2) · Advanced Center for Specialty Care (1) · American University of Beirut Medical Center (1) · Asan Medical Center (1) · Ayman Magd Eldin Mohammad Sadek (1) · Genuine Research Center, Egypt (1) · HK inno.N Corporation (1) · IBSA Institut Biochimique SA (1) · Indiana University (1) · Kaohsiung Medical University Chung-Ho Memorial Hospital (1) · M.D. Anderson Cancer Center (1) · National Cheng-Kung University Hospital (1) · Northwestern University (1)
United States (34) · Poland (7) · Canada (5) · Mexico (5) · China (4) · South Korea (4) · Australia (3) · Colombia (3) · Czechia (3) · Hungary (3) · Italy (3) · Latvia (3) · Lithuania (3) · Slovakia (3) · Belgium (2)
Lihua Wu, Doctor (2) · Ahmed Elshafeey, Ph.D. Pharma (1) · Akrawit Pulsombat, Doctor (1) · Ayman Sadek, MD (1) · Bor-Shyang Sheu, MD (1) · Brant K Oelschlager, MD (1) · David I. Rosenthal, MD, MA, BA (1) · Deng-Chyang Wu, MD, PhD (1) · Eunji Kim (1) · Jeffrey A Alexander, MD (1)
PMID 19735233, PMID 21129076, PMID 20195905, PMID 23451835, PMID 24118079, PMID 19183157, PMID 19681809, PMID 19210298, PMID 19392864, PMID 21118280, PMID 21224838, PMID 21716130, PMID 22155561, PMID 22464259, PMID 23333143, PMID 28780072, PMID 28916953, PMID 30445008, PMID 30625462, PMID 31067538, PMID 31118571, PMID 31338800, PMID 32095968, PMID 32949568, PMID 33659261, PMID 33705573, PMID 34642267, PMID 35184616, PMID 35973148, PMID 35979162, PMID 36057730, PMID 36117573, PMID 37885233, PMID 40383216
2014 (1)